SK bioscience, a global innovative vaccine and biotech company committed to promoting human health from prevention to cure, announced that the company has completed a major expansion of its vaccine production facility, L HOUSE, in Andong to strengthen its global infrastructure and accelerate entry into the global vaccine market.
The facility recently received building use approval from the City of Andong. The approval is an official certification issued by local authorities confirming the safety and suitability of newly constructed or expanded buildings for use.
The expansion aims to establish commercial-scale production capacity for GBP410, a 21-valent pneumococcal conjugate vaccine (PCV) candidate jointly developed with global pharmaceutical company Sanofi. Through joint investment, SK bioscience added two floors to the existing vaccine manufacturing department in L HOUSE, which created approximately 4,200㎡ of new space.
SK bioscience and Sanofi expect to leverage the scientific and technical know-how of both companies, including SK bioscience’s advanced technology and production capacity and Sanofi’s expertise in global product development, regulatory affairs and in launching innovative vaccines to achieve rapid market share expansion worldwide.
Furthermore, in December 2024, the two companies expanded their collaboration beyond the development and commercialization of GBP410. The expanded agreement aims to co-develop next-generation PCVs for both pediatric and adult populations with the potential to provide broader protection than those currently licensed, further strengthening the companies’ pneumococcal development pipeline.
Jaeyong Ahn, CEO of SK bioscience, said, “The expansion of L HOUSE marks a key milestone in establishing the facility as a global vaccine hub. Through our successful partnership with Sanofi, we will continue to lead as Korea’s premier vaccine company and contribute to advancing global public health.”
Comments powered by CComment